EF Hutton Maintains Buy on Humacyte, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Humacyte (NASDAQ:HUMA) and maintained a price target of $25.
October 28, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Humacyte and maintained a price target of $25, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $25 price target by EF Hutton suggests a positive outlook for Humacyte, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100